PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 12365285

[Cardiac tissue engineering].

Christof Stamm·Gustav Steinhoff
View original source ↗Export metadata ↓

Abstract

BACKGROUND: Cardiac tissue engineering is a relatively new interdisciplinary approach to replace diseased cardiovascular tissues with vital structures based on autologous cells. VARIOUS FORMS: This includes the re-seeding of decellularized allogenic or xenogenic scaffolds with autologous cells, the fabrication of organoids based on artificial, biodegradable polymers, and cell transplantation in solid organs. FUTURE CLINICAL APPLICATION: Tissue engineering heart valves, vascular grafts, as well as transplantation of contractile cells or stem cells for myocardial regeneration are not far from their first clinical application. Even though the development of an entirely tissue engineered replacement heart is not yet conceivable, tissue engineering strategies will most likely lead to a significant improvement in the treatment of both acquired and congenital heart disease.

Explore related subjects

Cell TransplantationForecastingHeart ValvesHumansMyocardial ContractionMyocardiumRegenerationTissue EngineeringEnglish AbstractJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Christof Stamm, Gustav Steinhoff. 2002. [Cardiac tissue engineering].. https://doi.org/10.1007/s00059-002-2383-6

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2003

Cell-based therapy of chronic degenerative diseases of the central nervous system.

The traditional methods of pharmacotherapy of the degenerative diseases of the central nervous system do not frequently allow one to achieve the desired clinical effect. The fundamentally new approach for the treatment of severe neurological diseases is provided by the methods of biological medicine, in particular, transplantation of a complex of fetal tissues. Cell-based therapy was used to treat patients with multiple sclerosis; ante-, intra- and postnatal lesions; consequences of hemorrhagic and ischemic apoplexies; neuritis of facial nerve; sclerosis; Parkinson's disease; Alzheimer's disease; epilepsy and other types of pathologic process. The source material for obtaining a suspension of cells was the fetuses of allogenic origin. The suspension of brain cells in amounts of up to 1.5 x 10(8) cells and vitality not less than 40% was administered to the patients into liquor spaces using the method of endolumbar puncture. The total number of transplantations was 1900. Practically in all the cases FT was tolerated well. Positive clinical and immunologic changes were observed in the majority of the patients, thus, remission induction (in the patients with the progressive course of multiple sclerosis) for a period over 12 months was registered in 87.5% of the cases. Noteworthy that considerable changes were observed in immunograms: depression of antibody levels to brain-specific proteins, native and denatured DNA; quantitative and qualitative improvement of lymphocyte subpopulation indices, positive changes in the immunoregulatory index. Clinically, in 69% of the cases there was an improvement in more than one neurological defect and a change in the values of the Kurtzke scale towards a decrease by 2-3 points. The conduct of cell therapy with the MS patients under the acute process conditions after liquorosorption allowed the arresting of clinical manifestations and the creation of preconditions for further restoration. The retrobulbar transplantations provided a quick arrest of the retrobulbar neuritis clinical symptoms and in one case an almost complete restoration of vision in the patient with amaurosis (blindness). The remission duration has a marked direct dependence on the number of courses of endolumbar transplantations. Thus, the method of cell therapy with the use of human tissue transplantations is safe and can be used for different neurodegenerative lesions of the central nervous system. The high efficacy of the method suggests the possibility and necessity of using this method as an alternative of classical pharmacological therapy. An important element of cell therapy is the control after the state of the patient's immunity system.

Cell Transplantation↗
PubMed2003

Skeletal muscle as an artificial endocrine tissue.

Muscle has the ability to take up and express engineered genes and, because it is a post-mitotic tissue, their half-life of expression is prolonged. Although muscle is not regarded as a secretory tissue, in many cases, the gene products enter the systemic circulation. The possibility exists, therefore, of using this approach to alter levels of endocrine and paracrine factors. As a therapeutic procedure, this method has an advantage over the administration of the peptide/protein, which has a relatively short half-life and requires repeated injections. Engineered genes in plasmid or viral vectors under the control of a muscle-specific regulatory sequence may be introduced by intramuscular injection or by the introduction of transfected myoblasts. The latter is also being used in bioreactors to produce medicinal proteins/peptides in vitro as these offer some advantages over bacterial expression systems. However, for gene therapy purposes, there are still safety issues to be addressed.

Cell Transplantation↗